Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE for each country, as well as annualized event counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan; we use 10 years for the rest of the countries.

Clarivate Epidemiology’s VTE forecast will answer the following questions:

  • Of all diagnosed VTE events, how many in each country are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE over the forecast period?
  • How will improvements in healthcare access and diagnostic technology affect the epidemiology of VTE in the low-income countries over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts eight VTE patient populations as follows:

  • Diagnosed VTE events.
  • Diagnosed DVT events.
  • Diagnosed PE events.
  • Diagnosed DVT events by drug treatment.
  • Diagnosed PE events by Drug treatment.
  • Diagnosed VTE events by etiology.
  • Diagnosed VTE events by cancer association.
  • Diagnosed VTE events by recurrence.

Note: Coverage may vary by country and region.

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Atrial Fibrillation – Landscape & Forecast – Disease Landscape & Forecast (G7)
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF can lead to blood clots, increasing the risk of stroke…